Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Trevi Therapeutics
52 Charter Ridge Road
New Haven, CT 6482
Phone: 203-304-2499
www.trevitherapeutics.com

Trevi Therapeutics, Inc. is a drug development company founded in 2011 focused on developing T111 for the severe chronic itching condition known as pruritus. Pruritus is manifested in various dermatological, metabolic, hematologic and neuronal conditions. The Company is pursuing uremic pruritus as the lead indication. Uremic pruritus is a persistent and debilitating itching in patients on dialysis that has been linked to increased mortality. T111 is an oral extended release opioid with a unique dual agonist/antagonist mechanism of action, which has been shown in both animal and human clinical studies as being effective in pruritus.

Key Contact
Name
Jennifer Good
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
12/18/12 $10,000,000 Series A TPG Biotech
undisclosed
06/04/14 $25,000,000 Series B TPG Biotech
undisclosed
07/20/17 $50,500,000 Series C Aperture Venture Partners
Lundbeckfonden Ventures
Omega Funds
TPG Biotech
undisclosed


Featured Reading